Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 1999

View Archived Issues

OraVax, Peptide Therapeutics and Pasteur Merieux Connaught announce agreements

Novel class of PAF antagonists presented by Searle

Phthalimide derivatives from JT selectively inhibit IL-5 and IgE production

Improved treatments for NIDDM in development at Dr. Reddy's and Reddy-Cheminor

Inhibitors of cGMP phosphodiesterases discovered at Bayer

Selective COX-2 inhibitors evaluated for antiinflammatory and analgesic effects at Grelan

Daiichi patents broad-spectrum antibacterial series

Otsuka discovers new platelet aggregation inhibitors and antithrombotic agents

Grant will help Copernicus develop novel targeted CF gene therapy

Neurobiological Technologies awarded SBIR grant for Xerecept development

Gensia Sicor establishes marketing agreement with Abbott

BioFocus and Pharmacia & Upjohn join forces in drug discovery

Phase III trial for angina treatment begins at international sites

Increased PKC activity activity and role for PKC-beta inhibitors in heart failure

FDA advisory committee recommends approval of Natrecor

Genentech and Schwarz enter collaboration for GH products

New herpes vaccine from Cel-Sci proves effective in protecting mice

CPMP recommends approval of Paxene for AIDS-related KS

First market introduction for new asthma treatment --Seretide Diskus

Genetix and Cordis to develop angiogenic gene therapy products for cardiovascular disease

Regulatory plans for gatifloxacin outlined by Kyorin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...